Pharmacokinetic and pharmacodynamic characterisation of an anti-mouse TNF receptor 1 domain antibody formatted for in vivo half-life extension

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Goodall, Laura J ^a   Ovecka, Milan ^a   Rycroft, Daniel ^a   Friel, Sarah L ^a   Sanderson, Andrew ^a   Mistry, Prafull ^a   Davies, Marie L ^a   Stoop, A Allart ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR AFFECTING AGENT; CYTOKINE RECEPTOR ANTAGONIST; DMS 5538; DMS 5540; EPITOPE; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1 DOMAIN ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; DMS5540; HYBRID PROTEIN; NANOBODY; TNFRSF1A PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; EPITOPE MAPPING; HOMEOSTASIS; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; L929 CELL LINE; LIGAND BINDING; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; RECEPTOR BINDING; RESIDUE ANALYSIS; SIGNAL TRANSDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CELL LINE; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CELL LINE; EPITOPES; HUMANS; INTERLEUKIN-6; MICE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SINGLE-DOMAIN ANTIBODIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84944810504     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137065     Document Type: Article

References (32)

1. Aggarwal BB. Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745-756. PMID: 12949498
2. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487-501. PMID: 11239407
3. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003;9:1245-1250. PMID: 14520364
4. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr, Goeddel DV et al. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA. 1991;88:9292-9296. PMID: 1718003
5. Aggarwal BB. Editorial: Balancing Tumor Necrosis Factor Receptor I and Tumor Necrosis Factor Receptor II Jointly for Joint Inflammation. Arthritis Rheumatol. 2014;66:2657-2660. doi: 10.1002/art. 38753 PMID: 24965670
6. Wajant H, Scheurich P. TNFR1-induced activation of the classical NF-kappaB pathway. FEBS J. 2011;278:862-876. doi: 10.1111/j.1742-4658.2011.08015.x PMID: 21232017
7. Kim EY, Priatel JJ, Teh SJ, Teh HS. TNF receptor type 2 (p75) functions as a costimulator for antigendriven T cell responses in vivo. J Immunol. 2006;176:1026-1035. PMID: 16393990
8. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov. 2010;9:482-493. doi: 10.1038/nrd3030 PMID: 20489699
9. Naude PJ, Den Boer JA, Luiten PG, Eisel UL. Tumor necrosis factor receptor cross-talk. FEBS J. 2011;278:888-898. doi: 10.1111/j.1742-4658.2011.08017.x PMID: 21232019
10. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149-160. PMID: 18161752
11. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature. 1985;318:665-667. PMID: 3001529
12. Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83:793-802. PMID: 8521496
13. Erickson SL, De Sauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 1994;372:560-563. PMID: 7990930
14. Pfeffer K, Matsuyama T, Kündig TM, Wakeham A, Kishihara K, Shahinian A et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73:457-467. PMID: 8387893
15. Rothe J, Lesslauer W, Lötscher H, Lang Y, Koebel P, Kontgen F et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364:798-802. PMID: 8395024
16. Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Nophar Y et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem. 1990;265:14497-14504 PMID: 1696947
17. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989;341:544-546. PMID: 2677748
18. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. Domain antibodies: proteins for therapy. Trends Biotechnol. 2003;21:484-490. PMID: 14573361
19. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel. 2008;21:283-288. doi: 10.1093/protein/gzm067 PMID: 18387938
20. Doyle ML, Tian SS, Miller SG, Kessler L, Baker AE, Brigham-Burke MR et al. Selective binding and oligomerization of the murine granulocyte colony-stimulating factor receptor by a low molecular weight, nonpeptidyl ligand. J Biol Chem. 2003;278:9426-9434. PMID: 12524421
21. Evans TJ. Bioassay for tumor necrosis factors-alpha and -beta. Mol Biotechnol. 2000;15:243-248. PMID: 10986700
22. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351-2354. PMID: 10875917
23. Deng GM, Zheng L, Chan FK, Lenardo M. Amelioration of inflammatory arthritis by targeting the preligand assembly domain of tumor necrosis factor receptors. Nat Med. 2005;11:1066-1072 PMID: 16170321
24. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell. 1993;73:431-445. PMID: 8387891
25. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52:83-124. doi: 10.1007/s40262-012-0027-4 PMID: 23299465
26. McCann FE, Perocheau DP, Ruspi G, Blazek K, Davies ML, Feldmann M et al. Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol. 2014;66:2728-2738. doi: 10.1002/art.38755 PMID: 24965881
27. Shibata H, Yoshioka Y, Ohkawa A, Minowa K, Mukai Y, Abe Y et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem. 2008;283:998-1007. PMID: 18003610
28. Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol. 2007;179:1872-83. PMID: 17641054
29. Sheehan KC, Pinckard JK, Arthur CD, Dehner LP, Goeddel DV, Schreiber RD et al. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med. 1995;181:607-17. PMID: 7836916
30. Kudo H, Takahara T, Yata Y, Kawai K, Zhang W, Sugiyama T et al. Lipopolysaccharide triggered TNFalphainduced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J Hepatol. 2009;51:168-75. doi: 10.1016/j.jhep. 2009.02.032 PMID: 19446916
31. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation. 2009;119:1386-1397. doi: 10.1161/CIRCULATIONAHA.108.802918 PMID: 19255345
32. Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med. 2001;193:427-434. PMID: 11181695